- Home
- PRZO vs TXMD Comparison
PRZO vs TXMD Comparison
Compare PRZO & TXMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PRZO | TXMD |
|---|---|---|
| Founded | 2014 | 2008 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.1M | 21.3M |
| IPO Year | 2023 | N/A |
Fundamental Metrics
Financial Performance| Metric | PRZO | TXMD |
|---|---|---|
| Price | $1.30 | $1.76 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 456.9K | 126.7K |
| Earning Date | 08-28-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.03 |
| Revenue | $1,007,440.00 | ★ $2,796,000.00 |
| Revenue This Year | N/A | $427.09 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $277.12 |
| Revenue Growth | ★ 80.42 | 75.19 |
| 52 Week Low | $0.53 | $0.70 |
| 52 Week High | $3.16 | $2.44 |
Technical Indicators
Market Signals| Indicator | PRZO | TXMD |
|---|---|---|
| Relative Strength Index (RSI) | 45.18 | 54.10 |
| Support Level | $1.25 | $1.46 |
| Resistance Level | $1.51 | $2.01 |
| Average True Range (ATR) | 0.07 | 0.16 |
| MACD | -0.00 | -0.00 |
| Stochastic Oscillator | 17.31 | 48.28 |
Price Performance
Historical ComparisonAbout PRZO ParaZero Technologies Ltd.
ParaZero Technologies Ltd is an aerospace company that is focused on drone safety systems and engaged in the business of designing, developing, and providing autonomous parachute safety systems for commercial drones, also known as unmanned aerial systems. The ParaZero SafeAir system of the company applies real-time data analytics to identify and mitigate flight risks autonomously and increase safety for bystanders while protecting the loss of expensive drones, equipment, and payloads.
About TXMD TherapeuticsMD Inc.
TherapeuticsMD Inc is a pharmaceutical royalty company, currently receiving royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. The company and its subsidiaries (i) granted Mayne Pharma an exclusive license to commercialize its IMVEXXY, BIJUVA and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands (collectively, the "Licensed Products") in the United States and its possessions and territories, (ii) assigned to Mayne Pharma its exclusive license to commercialize ANNOVERA (together with the Licensed Products, collectively, the "Products") in the United States and its possessions and territories.